The safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented.
We retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from April 2007 to May 2016 with an update in November 2019.
Twenty-seven patients with a history of IBD (Crohn's disease, 
Bevacizumab combined with chemotherapy is safe in cancer patients with moderately active or quiescent IBD.